SynthesisZhongguo fei ai za zhi = Chinese journal of lung cancer2013
[Meta-analysis of association between E-cadherin promoter methylation and lung cancer risk].
Synthesis in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
- Aberrant methylation ofJournal of Cancer · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveAs a member of the cadherin superfamily, E-cadherin plays a critical role in the maintenance of cell polarity and integrity. And E-cadherin was reported to be down-regulated and closely related to tumor initiation, invasion and metastasis. There have been a number of studies investigating the methylation of E-cadherin promoter in relation to various cancers. However, the association between E-cadherin promoter methylation and lung cancer risk is controversial. The aim of the present study is to evaluate the association of E-cadherin promoter methylation with risk of lung cancer by conducting a systematic meta-analysis.
methodsRelevant studies were identified by searches of PubMed/MedLine and EMBASE databases before March 2013. Combined odds ratio (OR) and 95% confidence interval (CI) were used to assess the strength of the association between E-cadherin promoter methylation and lung cancer risk.
resultsA total of 1,288 samples from 13 independent studies were included in the meta-analysis. Overall, a significant association was observed between E-cadherin promoter methylation and lung cancer risk (OR=4.04, 95%CI: 2.00-8.13, P<0.001). Subgroup analyses by ethnic revealed that lung cancer risk was increased for individuals carrying the methylated E-cadherin in Asian and Caucasian populations (OR=3.28, 95%CI: 1.20-8.92; OR=5.72, 95%CI: 2.40-13.62).
conclusionsThe present meta-analysis indicates that the methylation of E-cadherin promoter is associated with risk of lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.